This Candin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as increased investments in healthcare infrastructure, the expansion of public health campaigns, a rise in fungal infections, greater adoption of minimally invasive diagnostic methods, and heightened awareness of fungal infections.
The expected growth in the forecast period is driven by increasing prevalence of immunocompromised conditions, growing awareness among healthcare professionals about antifungal resistance, a rise in clinical trials, the growing incidence of hospital-acquired fungal infections, and a stronger focus on personalized antifungal treatments. Key trends in the forecast period include technological advancements, point-of-care diagnostics, molecular diagnostic technologies, bioinformatics, and wearable health technology.
The increasing prevalence of tuberculosis (TB) is expected to significantly drive the growth of the candin market. Tuberculosis, a contagious disease caused by mycobacterium tuberculosis, primarily affects the lungs but can spread to other parts of the body. The rise in TB cases can be attributed to factors such as increased transmission from untreated or undiagnosed cases, the emergence of drug-resistant TB strains, gaps in healthcare access, population displacement, and co-infections such as HIV that weaken immunity. Candin is used as a control in skin testing to evaluate cell-mediated immunity, distinguishing between immune responses caused by TB and nonspecific reactions in individuals with compromised immune function. For example, in March 2023, the Centers for Disease Control and Prevention (CDC) reported 8,300 TB cases in the United States in 2022, up from 7,874 cases in 2021. As the number of TB cases increases, the demand for candin as part of diagnostic procedures to assess TB risk is expected to rise, thus driving market growth.
The growing demand for personalized medicine is also expected to contribute to the expansion of the candin market. Personalized medicine tailors healthcare and treatment based on individual patient characteristics, such as genetics and lifestyle. This approach is being propelled by advancements in genomics, artificial intelligence (AI), and biotechnology, enabling more targeted treatments. Candin aligns with this trend by offering diagnostic tools that help healthcare providers personalize treatment plans based on individual immune responses and genetic factors, improving treatment efficacy and minimizing adverse effects. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, marking a significant increase from the previous year. The growing focus on personalized and precision medicine is likely to support the demand for candin as a diagnostic tool, driving its market growth.
A key trend in the candin market is the formation of strategic partnerships to offer effective, non-invasive, and cost-efficient treatment options. Strategic partnerships, where organizations collaborate to leverage each other’s resources and expertise, play a pivotal role in enhancing product development, expanding market reach, and increasing innovation. For instance, in May 2023, Nielsen BioSciences entered into a licensing agreement with Maruho Co. Ltd. to sell Candin in Japan as a treatment for verruca vulgaris (common warts). Through this partnership, Maruho assumes the responsibility for further development and regulatory activities for Candin, marking a significant milestone in its market expansion. Such collaborations are expected to accelerate the availability and adoption of Candin in new markets, further driving its growth.
The key company operating in the candin market is Nielsen BioSciences Inc.
North America was the largest region in the candin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in candin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the candin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Candin is a purified extract derived from the Candida albicans organism, primarily used as a diagnostic skin test antigen to assess cell-mediated immunity. It works by inducing a delayed-type hypersensitivity (DTH) response in individuals with intact immune systems, making it an effective tool for evaluating immune competency. Candin is commonly used in healthcare settings to detect conditions such as anergy in patients suspected of having immunosuppressive disorders.
The main indications for candin include candidiasis and thrush. Candidiasis is a fungal infection caused by the overgrowth of Candida species, often affecting the mouth, throat, skin, and genital area. Candin is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The candin market research report is one of a series of new reports that provides candin market statistics, including candin industry global market size, regional shares, competitors with a candin market share, detailed candin market segments, market trends and opportunities, and any further data you may need to thrive in the candin industry. This candin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The candin market consists of sales of diagnostic skin test antigens, immunotherapy products, vaccines, serology kits and recombinant antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as increased investments in healthcare infrastructure, the expansion of public health campaigns, a rise in fungal infections, greater adoption of minimally invasive diagnostic methods, and heightened awareness of fungal infections.
The expected growth in the forecast period is driven by increasing prevalence of immunocompromised conditions, growing awareness among healthcare professionals about antifungal resistance, a rise in clinical trials, the growing incidence of hospital-acquired fungal infections, and a stronger focus on personalized antifungal treatments. Key trends in the forecast period include technological advancements, point-of-care diagnostics, molecular diagnostic technologies, bioinformatics, and wearable health technology.
The increasing prevalence of tuberculosis (TB) is expected to significantly drive the growth of the candin market. Tuberculosis, a contagious disease caused by mycobacterium tuberculosis, primarily affects the lungs but can spread to other parts of the body. The rise in TB cases can be attributed to factors such as increased transmission from untreated or undiagnosed cases, the emergence of drug-resistant TB strains, gaps in healthcare access, population displacement, and co-infections such as HIV that weaken immunity. Candin is used as a control in skin testing to evaluate cell-mediated immunity, distinguishing between immune responses caused by TB and nonspecific reactions in individuals with compromised immune function. For example, in March 2023, the Centers for Disease Control and Prevention (CDC) reported 8,300 TB cases in the United States in 2022, up from 7,874 cases in 2021. As the number of TB cases increases, the demand for candin as part of diagnostic procedures to assess TB risk is expected to rise, thus driving market growth.
The growing demand for personalized medicine is also expected to contribute to the expansion of the candin market. Personalized medicine tailors healthcare and treatment based on individual patient characteristics, such as genetics and lifestyle. This approach is being propelled by advancements in genomics, artificial intelligence (AI), and biotechnology, enabling more targeted treatments. Candin aligns with this trend by offering diagnostic tools that help healthcare providers personalize treatment plans based on individual immune responses and genetic factors, improving treatment efficacy and minimizing adverse effects. For instance, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, marking a significant increase from the previous year. The growing focus on personalized and precision medicine is likely to support the demand for candin as a diagnostic tool, driving its market growth.
A key trend in the candin market is the formation of strategic partnerships to offer effective, non-invasive, and cost-efficient treatment options. Strategic partnerships, where organizations collaborate to leverage each other’s resources and expertise, play a pivotal role in enhancing product development, expanding market reach, and increasing innovation. For instance, in May 2023, Nielsen BioSciences entered into a licensing agreement with Maruho Co. Ltd. to sell Candin in Japan as a treatment for verruca vulgaris (common warts). Through this partnership, Maruho assumes the responsibility for further development and regulatory activities for Candin, marking a significant milestone in its market expansion. Such collaborations are expected to accelerate the availability and adoption of Candin in new markets, further driving its growth.
The key company operating in the candin market is Nielsen BioSciences Inc.
North America was the largest region in the candin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in candin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the candin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Candin is a purified extract derived from the Candida albicans organism, primarily used as a diagnostic skin test antigen to assess cell-mediated immunity. It works by inducing a delayed-type hypersensitivity (DTH) response in individuals with intact immune systems, making it an effective tool for evaluating immune competency. Candin is commonly used in healthcare settings to detect conditions such as anergy in patients suspected of having immunosuppressive disorders.
The main indications for candin include candidiasis and thrush. Candidiasis is a fungal infection caused by the overgrowth of Candida species, often affecting the mouth, throat, skin, and genital area. Candin is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, clinics, ambulatory care centers, and home care settings.
The candin market research report is one of a series of new reports that provides candin market statistics, including candin industry global market size, regional shares, competitors with a candin market share, detailed candin market segments, market trends and opportunities, and any further data you may need to thrive in the candin industry. This candin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The candin market consists of sales of diagnostic skin test antigens, immunotherapy products, vaccines, serology kits and recombinant antigens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Candin Market Characteristics4. Candin Market Trends and Strategies5. Candin Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Candin Pricing Analysis & Forecasts30. Global Candin Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Candin Market32. Recent Developments in the Candin Market
3. Candin Market Biologic Drug Characteristics
6. Global Candin Growth Analysis and Strategic Analysis Framework
8. Candin Market Segmentation
9. Global Candin Epidemiology of Clinical Indications
10. Candin Market Regional and Country Analysis
11. Asia-Pacific Candin Market
12. China Candin Market
13. India Candin Market
14. Japan Candin Market
15. Australia Candin Market
16. South Korea Candin Market
17. Western Europe Candin Market
18. UK Candin Market
19. Germany Candin Market
20. France Candin Market
21. Eastern Europe Candin Market
22. North America Candin Market
23. USA Candin Market
24. Canada Candin Market
25. South America Candin Market
26. Middle East Candin Market
27. Africa Candin Market
28. Candin Market Competitive Landscape and Company Profiles
29. Global Candin Market Pipeline Analysis
33. Candin Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Candin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on candin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for candin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The candin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Candidiasis; Thrush2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Nielsen BioSciences Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Nielsen BioSciences Inc.
